Abstract
The authors review the clinical, radiological, electrophysiological, pathological, and molecular aspects of Nasu–Hakola disease (polycystic lipomembranous osteodysplasia with sclerosing leukoencephalopathy or PLOSL). Nasu-Hakola disease is a unique disease characterized by multiple bone cysts associated with a peculiar form of neurodegeneration that leads to dementia and precocious death usually during the fifth decade of life. The diagnosis can be established on the basis of clinical and radiological findings. Recently, molecular analysis of affected families revealed mutations in the DAP12 (TYROBP) or TREM2 genes, providing an interesting example how mutations in two different subunits of a multi-subunit receptor complex result in an identical human disease phenotype. The association of PLOSL with mutations in the DAP12 or TREM2 genes has led to improved diagnosis of affected individuals. Also, the possible roles of the DAP12/TREM2 signaling pathway in microglia and osteoclasts in humans are just beginning to be elucidated. Some aspects of this peculiar signaling pathway are discussed here.
Similar content being viewed by others
REFERENCES
Abrikossoff, A. (1929). Über das Schicksal der spontan auftretenden Fettgranulome (lipophagen Granulome). Verh. Dtsch. Ges. Pathol. 24:57-64.
Ahn, S., Yoo, M., Lee, S., and Choi, E. (1996). A clinical and histopathological study of 22 patients with membranous lipodystrophy. Clin. Exp. Dermatol. 21:269-272.
Akai, M., Tateishi, A., Cheng, C. H., Morii, K., Abe, M., Ohno, T., and Ben, M. (1977). Membranous lipodystrophy: A clinicopathological study of six cases. J. Bone Joint Surg. Am. 59:802-809.
Albright, A. V., Shieh, J. T., Itoh, T., Lee, B., Pleasure, D., O'Connor, M. J., Doms, R. W., and Gonzalez-Scarano, F. (1999). Microglia express CCR5, CXCR4, and CCR3, but of these, CCR5 is the principal coreceptor for human immunodeficiency virus type 1 dementia isolates. J. Virol. 73:205-213.
Amano, N., Iwabuchi, K., Sakai, H., Yagishita, S., Itoh, Y., Iseki, E., Yokoi, S., Arai, N., and Kinoshita, J. (1987). Nasu-Hakola's disease (membranous lipodystrophy). Acta Neuropathol. (Berl.) 74:294-299.
Araki, T., Ohba, H., Monzawa, S., Sakuyama, K., Hachiya, J., Seki, T., Takahashi, Y., and Yamaguchi, M. (1991). Membranous lipodystrophy: MR imaging appearance of the brain. Radiology 180:793-797.
Bacon, K. B., and Harrison, J. K. (2000). Chemokines and their receptors in neurobiology: Perspectives in physiology and homeostasis. J. Neuroimmunol. 104:92-97.
Bakker, A. B., Baker, E., Sutherland, G. R., Phillips, J. H., and Lanier, L. L. (1999). Myeloid DAP12-associating lectin (MDL)-1 is a cell surface receptor involved in the activation of myeloid cells. Proc. Natl. Acad. Sci. U.S.A. 96:9792-9796.
Bakker, A. B., Hoek, R. M., Cerwenka, A., Blom, B., Lucian, L., McNeil, T., Murray, R., Phillips, L. H., Sedgwick, J. D., and Lanier, L. L. (2000). DAP12-deficient mice fail to develop autoimmunity due to impaired antigen priming. Immunity 13:345-353.
Banchereau, J., and Steinman, R. M. (1998). Dendritic cells and the control of immunity. Nature. 19:245-252.
Bird, T. D., Koerker, R. M., Leaird, B. J., Vlcek, B. W., and Thorning, D. R. (1983). Lipomembranous polycystic osteodysplasia (brain, bone, and fat disease): A genetic cause of presenile dementia. Neurology 33:81-86.
Blair, H. C. (1998). How the osteoclast degrades bone. Bioessays 20:837-846.
Blair, H. C., Zaidi, M., and Schlesinger, P. H. (2002). Mechanisms balancing skeletal matrix synthesis and degradation. Biochem. J. 364:329-341.
Bouchon, A., Dietrich, J., and Colonna, M. (2000). Cutting edge: Inflammatory responses can be triggered by TREM-1, a novel receptor expressed on neutrophils and monocytes. J. Immunol. 164:4991-4995.
Bouchon, A., Hernandez-Munain, C., Cella, M., and Colonna, M. (2001). A DAP12-mediated pathway regulates expression of CC chemokine receptor 7 and maturation of human dendritic cells. J. Exp. Med. 194:1111-1122.
Brown, D. R. (2001). Microglia and prion disease. Microsc. Res. Tech. 54:71-80.
Campbell, K. S., and Colonna, M. (1999). DAP12: A key accessory protein for relaying signals by natural killer cell receptors. Int. J. Biochem. Cell. Biol. 31:631-636.
Chabas, D., Baranzini, S. E., Mitchell, D., Bernard, C. C., Rittling, S. R., Denhardt, D. T., Sobel, R. A., Lock, C., Karpuj, M., Pedotti, R., Heller, R., Oksenberg, J. R., and Steinman, L. (2001). The influence of the proinflammatory cytokine, osteopontin, on autoimmune demyelinating disease. Science 294:1731-1735.
Chung, D. H., Seaman, W. E., and Daws, M. R. (2002). Characterization of TREM-3, an activating receptor on mouse macrophages: Definition of a family of single Ig domain receptors on mouse chromosome 17. Eur. J. Immunol. 32:59-66.
Compston, J. E. (2002). Bone marrow and bone: A functional unit. J. Endocrinol. 173:387-394.
Coraci, I. S., Husemann, J., Berman, J. W., Hulette, C., Dufour, J. H., Campanella, G. K., Luster, A. D., Silverstein, S. C., and El-Khoury, J. B. (2002). CD36, a class B scavenger receptor, is expressed on microglia in Alzheimer's disease brains and can mediate production of reactive oxygen species in response to beta-amyloid fibrils. Am. J. Pathol. 160:101-112.
Cummings, J. L. (1986). Subcortical dementia. Neuropsychology, neuropsychiatry, and pathophysiology. Br. J. Psychiatr 149:682-697.
Diefenbach, A., Tomasello, E., Lucas, M., Jamieson, A. M., Hsia, J. K., Vivier, E., and Raulet, D. H. (2002). Selective associations with signaling proteins determine stimulatory versus costimulatory activity of NKG2D. Nat. Immunol. 3:1142-1149.
Deisenhammer, F., Willeit, J., Schmidauer, C., Kiechl, S., and Pohl, P. (1993). [Membranous lipodystrophy (Nasu-Hakola disease)]. Nervenarzt. 64:263-265.
Dietrich, J., Cella, M., Seiffert, M., Buhring, H. J., and Colonna, M. (2000). Cutting edge: Signal-regulatory protein beta 1 is a DAP12-associated activating receptor expressed in myeloid cells. J. Immunol. 164:9-12.
Ducy, P., Schinke, T., and Karsenty, G. (2000). The osteoblast: A sophisticated fibroblast under central surveillance. Science 289:1501-1504.
Duong, L. T., and Rodan, G. A. (2001). Regulation of osteoclast formation and function. Ver. Endocr. Metab. Disord. 2:95-104.
Gallucci, S., Lolkema, M., and Matzinger, P. (1999). Natural adjuvants: Endogeneous activators of dendritic cells. Nat. Med. 11:1249-1255.
Gebicke-Haerter, P. J. (2001). Microglia in neurodegeneration: Molecular aspects. Microsc. Res. Tech. 54:47-58.
Gebicke-Haerter, P. J., Spleiss, O., Ren, L. Q., Li, H., Dichmann, S., Norgauer, J., and Boddeke, H. W. (2001). Microglial chemokines and chemokine receptors. Prog. Brain Res. 132:525-532.
Gebicke-Haerter, P. J., Van Calker, D., Norenberg, W., and Illes, P. (1996). Molecular mechanisms of microglial activation. plications for regeneration and neurodegenerative diseases. Neurochem. Int. 29:1-12.
Gilfillan, S., Ho, E. L., Cella, M., Yokoyama, W. M., and Colonna, M. (2002). NKG2D recruits two distinct adapters to trigger NK cell activation and costimulation. Nat. Immunol. 3:1150-1155.
Gonzalez-Scarano, F., and Baltuch, G. (1999). Microglia as mediators of inflammatory and degenerative diseases. Annu. Rev. Neurosci. 22:219-240.
Greenfield, E. M., Bi, Y., and Miyauchi, A. (1999). Regulation of osteoclast activity. Life Sci. 65:1087-1102.
Hakola, H. P. (1972). Neuropsychiatric and genetic aspects of a new hereditary disease characterized by progressive dementia and lipomembranous polycystic osteodysplasia. Acta Psychiatr. Scand. Suppl. 232:1-173.
Hakola, H. P., and Karjalanen, P. (1975). Bone mineral content in hereditary polycystic osteodysplasia associated with progressive dementia. Acta. Radiol. Diagn. 16:385-392.
Hakola, H. P. (1998). Benton's Visual Retention Test in patients with polycystic lipomembranous dysplasia with sclerosing leukoencephalopathy. Dement. Geriatr. Cogn. Disord. 9:39-43.
Hakola, H. P., Jarvi, O. H., and Sourander, P. (1970). Osteodysplasia polycystica hereditaria combined with sclerosing leucoencephalopathy, a new entity of the dementia praesenilis group. Acta Neurol. Scand. 46(Suppl 43):79.
Hakola, H. P., Karjalainen, P., and Virtama, P. (1988). Bone scintigraphy in polycystic lipomembranous osteodysplasia with sclerosing leukoencephalopathy. Nucl. Med. Commun. 9:1005-1011.
Hakola, H. P., and Partanen, V. S. (1983). Neurophysiological findings in the hereditary presenile dementia characterised by polycystic lipomembranous osteodysplasia and sclerosing leukoencephalopathy. J. Neurol. Neurosurg. Psychiatry 46:515-520.
Hakola, H. P., and Puranen, M. (1993). Neuropsychiatric and brain CT findings in polycystic lipomembranous osteodysplasia with sclerosing leukoencephalopathy. Acta Neurol. Scand. 88:370-375.
Halliday, G., Robinson, S. R., Shepherd, C., and Kril, J. (2000). Alzheimer's disease and inflammation: A review of cellular and therapeutic mechanisms. Clin. Exp. Pharmacol. Physiol. 27:1-8.
Harada, K. (1975). [A case of “membranous lipodystrophy (Nasu)” with emphasis on psychiatric and neuropathologic aspects (Author's Transl.)]. Folia Psychiatr. Neurol. Jpn. 29:169-177.
Hasegawa, Y., and Inagaki, Y. (1983). Membranous lipodystrophy (lipomembranous polycystic osteodysplasia). Two case reports. Clin. Orthop. 12:229-232.
Hill, P. A. (1998). Bone remodelling. Br. J. Orthod. 25:101-107.
Hull, M., Lieb, K., and Fiebich, B. L. (2002). Pathways of inflammatory activation in Alzheimer's disease: Potential targets for disease modifying drugs. Curr. Med. Chem. 9:83-88.
Kalimo, H., Sourander, P., Jarvi, O., and Hakola, P. (1994). Vascular changes and blood-brain barrier damage in the pathogenesis of polycystic lipomembranous osteodysplasia with sclerosing leukoencephalopathy (membranous lipodystrophy). Acta Neurol. Scand. 89:353-361.
Kaul, M., Garden, G. A., and Lipton, S. A. (2001). Pathways to neuronal injury and apoptosis in HIV-associated dementia. Nature 410:988-994.
Kaul, M., and Lipton, S. A. (1999). Chemokines and activated macrophages in HIV gp120-induced neuronal apoptosis. Proc. Natl. Acad. Sci. U.S.A. 96:8212-8216.
Kenny, A. M., and Raisz, L. G. (2002). Mechanisms of bone remodeling: Implications for clinical practice. J. Reprod. Med. 47:63-70.
Kitajima, I., Kuriyama, M., Usuki, F., Izumo, S., Osame, M., Suganuma, T., Murata, F., and Nagamatsu, K. (1989). Nasu-Hakola disease (membranous lipodystrophy). Clinical, histopathological and biochemical studies of three cases. J. Neurol. Sci. 91:35-52.
Kocer, N., Dervisoglu, S., Ersavasti, G., Altug, A., and Cokyuksel, O. (1994). Case report 867. Membranous lipodystrophy (polycystic lipomembranous osteodysplasia). Skeletal Radiol 23:577-579.
Kondo, T., Takahashi, K., Kohara, N., Takahashi, Y., Hayashi, S., Takahashi, H., Matsuo, H., Yamazaki, M., Inoue, K., Miyamoto, K., and Yamamura, T. (2002). Heterogeneity of presenile dementia with bone cysts (Nasu-Hakola disease). Three genetic forms. Neurology 59:1105-1107.
Langford, D., and Masliah, E. (2001). Crosstalk between components of the blood brain barrier and cells of the CNS in microglial activation in AIDS. Brain Pathol. 11:306-312.
Lanier, L. L. (1998). NK cell receptors. Annu. Rev. Immunol. 16:359-393.
Lanier, L. L., and Bakker, A. B. (2000). The ITAM-bearing transmembrane adaptor DAP12 in lymphoid and myeloid cell function. Immunol. Today 21:611-614.
Lanier, L. L., Corliss, B., Wu, J., and Phillips, J. H. (1998a). Association of DAP12 with activating CD94/NKG2C NK cell receptors. Immunity 8:693-701.
Lanier, L. L., Corliss, B. C., Wu, J., Leong, C., and Phillips, J. H. (1998b). Immunoreceptor DAP12 bearing a tyrosine-based activation motif is involved in activating NK cells. Nature. 391:703-707.
Machinami, R. (1984). Incidence of membranous lipodystrophy-like change among patients with limb necrosis caused by chronic arterial obstruction. Arch. Pathol. Lab. Med. 108:823-826.
Machinami, R. (2001). [Membranous lipodystrophy of the bone]. Ann. Pathol. 21:524-528.
Malandrini, A., Scarpini, C., Palmeri, S., Villanova, M., Parrotta, E., Tripodi, S., Giani, S., DeFalco, D., and Guazzi, G. C. (1996). Palatal myoclonus and unusual MRI findings in a patient with membranous lipodystrophy. Brain. Dev. 18:59-63.
Manolagas, S. C. (2000). Birth and death of bone cells: Basic regulatory mechanisms and implications for the pathogenesis and treatment of osteoporosis. Endocr. Rev. 21:115-137.
Matsushita, M., Oyanagi, S., Hanawa, S., Shiraki, H., and Kosaka, K. (1981). Nasu-Hakola's disease (membranous lipodystrophy). A case report. Acta Neuropathol. (Berl.) 54:89-93.
McVicar, D. W., Taylor, L. S., Gosselin, P., Willette-Brown, J., Mikhael, A. I., Geahlen, R. L., Nakamura, M. C., Linnemeyer, P., Seaman, W. E., Anderson, S. K., Ortaldo, J. R., and Mason, L. H. (1998). DAP12-mediated signal transduction in natural killer cells. A dominant role for the Syk protein-tyrosine kinase. J. Biol. Chem. 273:32934-32942.
Merrill, J. E. (1992). Proinflammatory and antiinflammatory cytokines in multiple sclerosis and central nervous system acquired immunodeficiency syndrome. J. Immunother. 12:167-170.
Minagar, A., Shapshak, P., Fujimura, R., Ownby, R., Heyes, M., and Eisdorfer, C. (2002). The role of macrophage/microglia and astrocytes in the pathogenesis of three neurologic disorders: HIV-associated dementia, Alzheimer disease, and multiple sclerosis. J. Neurol. Sci. 202:13.
Mitrovic, B., Martin, F. C., Charles, A. C., Ignarro, L. J., Anton, P. A., Shanahan, F., and Merrill, J. E. (1994). Neurotransmitters and cytokines in CNS pathology. Prog. Brain. Res. 103:319-330.
Miyazu, K., Kobayashi, K., Fukutani, Y., Nakamura, I., Hasegawa, H., Yamaguchi, N., and Saitoh, T. (1991). Membranous lipodystrophy (Nasu-Hakola disease) with thalamic degeneration: Report of an autopsied case. Acta Neuropathol. (Berl.) 82:414-419.
Moretta, A., Bottino, C., Vitale, M., Pende, D., Cantoni, C., Mingari, M. C., et al. (2001). Activating receptors and coreceptors involved in human natural killer cell-mediated cytolysis. Annu. Ver. Immunol. 19:197-223.
Motohashi, N., Shinohara, M., Shioe, K., Fukuzawa, H., Akiyama, Y., and Kariya, T. (1995). A case of membranous lipodystrophy (Nasu-Hakola disease) with unique MRI findings. Neuroradiology 37:549-550.
Nakamura, Y. (2002). Regulating factors for microglial activation. Biol. Pharm. Bull. 25:945-953.
Nasu, T., Tsukahara, Y., and Terayama, K. (1973). A lipid metabolic disease--“membranous lipodystrophy”--an autopsy case demonstrating numerous peculiar membrane-structures composed of compound lipid in bone and bone marrow and various adipose tissues. Acta Pathol. Jpn. 23:539-558.
Ohtani, Y., Miura, S., Tamai, Y., Kojima, H., and Kashima, H. (1979). Neutral lipid and sphingolipid composition of the brain of a patient with membranous lipodystrophy. J. Neurol. 220:77-82.
Okada, K., Hoshi, N., Kawamura, K., Sato, K., and Yamamoto, M. (1999). Membranocystic lesion in lumbar yellow ligament. Spine. 24:1147-1150.
Paloneva, J., Autti, T., Raininko, R., Partanen, J., Salonen, O., Puranen, M., Hakola, P., and Haltia, M. (2001). CNS manifestations of Nasu-Hakola disease: A frontal dementia with bone cysts. Neurology 56:1552-1558.
Paloneva, J., Kestila, M., Wu, J., Salminen, A., Bohling, T., Ruotsalainen, V., Hakola, P., Bakker, A. B., Phillips, J. H., Pekkarinen, P., Lanier, L. L., Timonen, T., and Peltonen, L. (2000). Loss-of-function mutations in TYROBP (DAP12) result in a presenile dementia with bone cysts. Nat. Genet. 25:357-361.
Paloneva, J., Manninen, T., Christman, G., Hovanes, K., Mandelin, J., Adolfsson, R., Bianchin, M., Bird, T., Miranda, R., Salmaggi, A., Tranebjaerg, L., Konttinen, Y., and Peltonen, L. (2002). Mutations in two genes encoding different subunits of a receptor signaling complex result in an identical disease phenotype. Am. J. Hum. Genet. 71:656-662.
Pazzaglia, U. E., Benazzo, F., Byers, P. D., Riboni, L., and Ceciliani, L. (1987). Pathogenesis of membranous lipodystrophy. Case report and review of the literature. Clin. Orthop. 279-287.
Pekkarinen, P., Hovatta, I., Hakola, P., Jarvi, O., Kestila, M., Lenkkeri, U., Adolfsson, R., Holmgren, G., Nylander, P. O., Tranebjaerg, L., Terwilliger, J. D., Lonnqvist, J., and Peltonen, L. (1998). Assignment of the locus for PLO-SL, a frontal-lobe dementia with bone cysts, to 19q13. Am. J. Hum. Genet. 62:362-372.
Preziuso, L., Muncibi, F., and Aglietti, F. G. (1992). A case of membranous lipodystrophy with skeletal involvement. Chir. Organi. Mov. 77:205-211.
Sageshima, M., Masuda, H., Kawamura, K., and Shozawa, T. (1987). Membranous lipodystrophy. Light and electron microscopic study of a biopsy case. Acta Pathol. Jpn. 37:281-290.
Sami, S., Liu, G., Hornicek, F., Cates, J. M., and Mankin, H. J. (2002). Membranous lipodystrophy. A case report. J. Bone Joint Surg. Am. 84-A:630-633.
Sauter, B., Albert, M. L., Francisco, L., Larson, M., Somersoon, S., and Bhardwaj, N. (2000). Consequences of cell death: Exposure to necrotic tumor cells, but not primary cells or apoptotic cells, introduces the maturation of immunostimulatory dendritic cells. J. Exp. Med. 191:411-416.
Schafer, C., Klunemann, H. H., Ibach, B., Mueller, J., Putzhammer, A., Trender-Gerhard, I., Schuierer, G., and Klein, H. E. (2002). [Presenile dementia in polycystic lipomembranous osteodysplasia]. Nervenarzt 73:879-882.
Sjolin, H., Tomasello, E., Mousavi-Jazi, M., Bartolazzi, A., Karre, K., Vivier, E., and Cerboni, C. (2002). Pivotal role of KARAP/DAP12 adaptor molecule in the natural killer cell-mediated resistance to murine cytomegalovirus infection. J. Exp. Med. 195:825-834.
Smith, K. M., Wu, J., Bakker, A. B., Phillips, J. H., and Lanier, L. L. (1998). Ly-49D and Ly-49H associate with mouse DAP12 and form activating receptors. J. Immunol. 161:7-10.
Stubgen, J. P., and Lotz, B. P. (1992). Membranous lipodystrophy. Clinical and electrophysiological observations in the first South African case. S. Afr. Med. J. 81:620-622.
Tanaka, J. (1980). Leukoencephalopathic alteration in membranous lipodystrophy. Acta Neuropathol. (Berl.) 50:193-197.
Tanaka, J. (2000). Nasu-Hakola disease: A review of its leukoencephalopathic and membranolipodystrophic features. Neuropathology 20(Suppl):S25-S29.
Teitelbaum, S. L. (2000). Bone resorption by osteoclasts. Science 289:1504-1508.
Teitelbaum, S. L., Tondravi, M. M., and Ross, F. P. (1997). Osteoclasts, macrophages, and the molecular mechanisms of bone resorption. J. Leukoc. Biol. 61:381-388.
Tomasello, E., Desmoulins, P.O., Chemin, K., Guia, S., Cremer, H., Ortaldo, J., Love, P., Kaiserlian, D., and Vivier, E. (2000). Combined natural killer cell and dendritic cell functional deficiency in KARAP/DAP12 loss-of-function mutant mice. Immunity 13:355-364.
Tranebjaerg, L., Schrader, H., and Paloneva, J. (2000). [Polycystic lipomembranous osteodysplasia]. Tidsskr. Nor. Laegeforen. 120:3196.
Ueki, Y., Kohara, N., Oga, T., Fukuyama, H., Akiguchi, I., Kimura, J., and Shibasaki, H. (2000). Membranous lipodystrophy presenting with palilalia: A PET study of cerebral glucose metabolism. Acta Neurol. Scand. 102:60-64.
Vaananen, H. K., Zhao, H., Mulari, M., and Halleen, J. M. (2000). The cell biology of osteoclast function. J. Cell. Sci. 113(Pt. 3):377-381.
Van Everbroeck, B., Dewulf, E., Pals, P., Lubke, U., Martin, J. J., and Cras, P. (2002). The role of cytokines, astrocytes, microglia and apoptosis in Creutzfeldt-Jakob disease. Neurobiol. Aging. 23:59-64.
Verloes, A., Maquet, P., Sadzot, B., Vivario, M., Thiry, A., and Franck, G. (1997). Nasu-Hakola syndrome: Polycystic lipomembranous osteodysplasia with sclerosing leucoencephalopathy and presenile dementia. J. Med. Genet. 34:753-737.
Wood, C. (1978). Membranous lipodystrophy of bone. Arch. Pathol. Lab. Med. 102:22-27.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Bianchin, M.M., Capella, H.M., Chaves, D.L. et al. Nasu–Hakola Disease (Polycystic Lipomembranous Osteodysplasia with Sclerosing Leukoencephalopathy—PLOSL): A Dementia Associated with Bone Cystic Lesions. From Clinical to Genetic and Molecular Aspects. Cell Mol Neurobiol 24, 1–24 (2004). https://doi.org/10.1023/B:CEMN.0000012721.08168.ee
Issue Date:
DOI: https://doi.org/10.1023/B:CEMN.0000012721.08168.ee